OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD

gerry2 (Post 14990) the statement is realistic, as it is entirely feasible to go from a PI/II Prosavin, directly into PIII, and AK actually said that recently.

Furthermore, you omitted another important part of the Prosavin article, as follows:

"The higher efficacy of ProSavin combined with the absence of side effects suggest that ProSavin could be used to replace current standard therapy with L-DOPA in late-stage Parkinson's disease. These new data add to the extensive preclinical data package that supports advancement of the product into human trials".





No wonder OXB expect Prosavin to potentially attract a partner during 2007. Infact, I think OXB's superb pipeline will lead to a take-over, either before or after a deal for TroVax imo.